Catalio Capital Management
Catalio Capital Management reported 47 stocks worth $538M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVLN (9.0%), BMY (5.8%) and BBIO (5.2%). Compared with Q2 2026, the fund opened new positions in ARWR, CELC and GH, added to AVLN, BMY and ASND, trimmed BBIO, JNJ and SNDX and sold out of GILD, INCY and AXSM.
Latest filing: what Catalio Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() AVLN Avalyn Pharma Inc | $48.4M | 9.0% | 1.7M | +23K (+1%) | 2 of 8 | |
| 2 | ![]() BMY Bristol Myers Squibb Co | $31.2M | 5.8% | 500K | +87K (+21%) | 5 of 8 | |
| 3 | ![]() BBIO Bridgebio Pharma Inc | $28M | 5.2% | 425K | −30K (−7%) | 7 of 8 | |
| 4 | ![]() PBLS Parabilis Medicines Inc Com | $26.6M | 4.9% | 824K | No change | 2 of 8 | |
| 5 | ![]() JNJ Johnson & Johnson | $26.3M | 4.9% | 99K | −39K (−28%) | 3 of 8 | |
| 6 | ![]() ASND Ascendis Pharma A/s | $23.1M | 4.3% | 101K | +70K (+219%) | 2 of 8 | |
| 7 | ![]() ARWR Arrowhead Pharmaceuticals in | $20.6M | 3.8% | 315K | New position | 1 of 8 | |
| 8 | ![]() SNDX Syndax Pharmaceuticals Inc | $19.2M | 3.6% | 1M | −192K (−16%) | 7 of 8 | |
| 9 | ![]() DFTX Definium Therapeutics Inc | $19M | 3.5% | 498K | −65K (−12%) | 3 of 8 | |
| 10 | ![]() CELC Celcuity Inc | $18.3M | 3.4% | 231K | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() GILD Gilead Sciences Inc | $34M | 269K |
![]() INCY Incyte Corp | $21.7M | 192K |
![]() AXSM Axsome Therapeutics Inc | $10.6M | 43K |
![]() DYN Dyne Therapeutics Inc | $5.4M | 245K |
![]() DNTH Dianthus Therapeutics Inc | $3.2M | 33K |
🔒 Free account: see all 6.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Catalio Capital Management 13F FAQ
What does Catalio Capital Management own?
Catalio Capital Management reported 47 stocks worth $538M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVLN (9.0%), BMY (5.8%) and BBIO (5.2%). The table above lists every position in the filing (the top 10 without an account).
What did Catalio Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 14 new positions, 13 added to, 14 trimmed and 6 sold out. New positions include ARWR, CELC and GH. It sold all of GILD, INCY and AXSM.
When will Catalio Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Catalio Capital Management's portfolio worth?
The Q3 2026 filing reports $538M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























